同仁堂科技(01666.HK):準許將"金釵石斛散【同仁堂】"在香港出售
格隆匯3月20日丨同仁堂科技(01666.HK)布,公司附屬公司同仁堂國藥於近日收到香港中醫藥管理委員會頒發的《中成藥註冊證明書》,準許將「金釵石斛散【同仁堂】」在香港出售。
藥品名稱:金釵石斛散【同仁堂】
註冊持有人及地址:北京同仁堂國藥有限公司,香港新界大埔工業邨大景街3號
註冊編號:HKC-18754證明書有效期限:至2030年1月23日止
據悉,「金釵石斛散【同仁堂】」功能主治爲用於熱病津傷,口感煩渴,胃陰不足,食少乾嘔,病後虛熱不退,陰虛火旺,骨蒸勞熱,目暗不明,筋骨痿軟。截止本公告日,同仁堂國藥就「金釵石斛散【同仁堂】」的研發投入累計約港幣2百萬元(金額未經審計),該產品暫未投入市場銷售。
本次同仁堂國藥取得香港中醫藥管理委員會簽發的中成藥註冊證明書後,同仁堂國藥生產的「金釵石斛散【同仁堂】」可在香港出售,有助於豐富同仁堂國藥產品線,有利於同仁堂國藥實施市場拓展。上述註冊證明書的取得暫不會對同仁堂國藥的生產經營和業績產生重大影響。藥品銷售容易受到香港地區政策環境變化、匯率波動、市場競爭等因素的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.